Mode of antiviral action of silver nanoparticles against HIV-1 by Lara, Humberto H et al.
RESEARCH Open Access
Mode of antiviral action of silver nanoparticles
against HIV-1
Humberto H Lara
*, Nilda V Ayala-Nuñez, Liliana Ixtepan-Turrent, Cristina Rodriguez-Padilla
Abstract
Background: Silver nanoparticles have proven to exert antiviral activity against HIV-1 at non-cytotoxic
concentrations, but the mechanism underlying their HIV-inhibitory activity has not been not fully elucidated. In this
study, silver nanoparticles are evaluated to elucidate their mode of antiviral action against HIV-1 using a panel of
different in vitro assays.
Results: Our data suggest that silver nanoparticles exert anti-HIV activity at an early stage of viral replication, most
likely as a virucidal agent or as an inhibitor of viral entry. Silver nanoparticles bind to gp120 in a manner that
prevents CD4-dependent virion binding, fusion, and infectivity, acting as an effective virucidal agent against cell-
free virus (laboratory strains, clinical isolates, T and M tropic strains, and resistant strains) and cell-associated virus.
Besides, silver nanoparticles inhibit post-entry stages of the HIV-1 life cycle.
Conclusions: These properties make them a broad-spectrum agent not prone to inducing resistance that could be
used preventively against a wide variety of circulating HIV-1 strains.
Background
According to the Joint United Nations Programme on
HIV/AIDS, an estimated 33 million people were living
with HIV in 2007, 2.7 million fewer than in 2001 [1].
Although the rate of new HIV infections has fallen in sev-
eral countries, the HIV/AIDS pandemic still stands as a
serious public health problem worldwide. The emergence
of resistant strains is one of the principal challenges to
containing the spread of the virus and its impact on
human health. In different countries, studies have shown
that 5%-78% of treated patients receiving antiretroviral
therapy are infected with HIV-1 viruses that are resistant
to at least one of the available drugs [2]. For these reasons,
there is a need for new anti-HIV agents that function over
viral stages other than retrotranscription or protease activ-
ity and that can be used for treatment and prevention of
HIV/AIDS dissemination [3].
Fusion or entry inhibitors are considered an attractive
option, since blocking HIV entry into its target cell
leads to suppression of viral infectivity, replication, and
the cytotoxicity induced by the virus-cell interaction [4].
Since 2005, only two fusion inhibitors have been
approved by the FDA (Enfurtivide and Maravirovic).
In addition to fusion inhibitors, virucidal agents are
urgently needed for HIV/AIDS prevention because they
directly inactivate the viral particle (virion), which pre-
vents the completion of the viral replication cycle. Viru-
cidal agents differ from virustatic drugs in that they act
directly and rapidly by lysing viral membranes on con-
tact or by binding to virus coat proteins [5]. These com-
pounds would directly interact with HIV-1 virions to
inactivate infectivity or prevent infection and could be
used as an approach to provide a defense against sexual
transmission of the virus [6].
Previously, we explored the antiviral properties of sil-
ver nanoparticles against HIV-1 and found by in vitro
assays that they are active against a laboratory-adapted
HIV-1 strain at non-cytotoxic concentrations. Images
obtained by high angle annular dark field (HAADF)
scanning transmission electron microscopy (STEM)
show gp120 as its possible molecular target. Using this
technique, a regular spatial arrangement of the silver
nanoparticles attached to HIV-1 virions was observed.
The center-to-center distance between the silver nano-
particles (~28 nm) was similar to the spacing of gp120
spikes over the viral membrane (~22 nm). It was
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the glycoprotein knobs wouldb ea t t r a c t i v es i t e sf o r
nanoparticle interaction [7 ] .H o w e v e r ,t h em e c h a n i s m
underlying the HIV-inhibitory activity of silver nanopar-
ticles was not fully elucidated.
Nanotechnology offers opportunities to re-explore bio-
logical properties of known antimicrobial compounds by
manipulation of their sizes. Silver has long been known
for its antimicrobial properties, but its medical applica-
tions declined with the development of antibiotics.
Nonetheless, Credés prophylaxis of gonococcal ophthal-
mia neonatorum remained the standard of care in many
countries until the end of the 20
th century [8]. Cur-
rently, silver sulfadiazine is listed by the World Health
Organization as an essential anti-infective topical medi-
cine [9]. Silver’sm o d eo fa c t i o ni sp r e s u m e dt ob e
dependent on Ag
+ ions, which strongly inhibit bacterial
growth through suppression of respiratory enzymes and
electron transport components and through interference
with DNA functions [10]. If silver as a bulk material
works, would nano-size silver be appealing? In medicine,
the potential of metal nanoparticles has been explored
for early detection, diagnosis, and treatment of diseases,
but their biological properties have largely remained
unexplored [11].
Silver nanoparticles have been studied for their anti-
microbial potential and have proven to be antibacterial
agents against both Gram-negative and Gram-positive
bacteria [12-16], and antiviral agents against the HIV-1
[17] hepatitis B virus [18] respiratory syncytial virus [19]
herpes simplex virus type 1 [20] and monkeypox virus
[21]. The development of silver nanoparticle products is
expanding. They are now used as part of clothing, food
containers, wound dressings, ointments, implant coat-
ings, and other items [22,23]; some silver nanoparticle
applications have received approval from the US Food
and Drug Administration [24].
To better understand the mode of action by which sil-
ver nanoparticles inactivate HIV-1 and their potential as
a virucidal agent, we used a panel of assays that
included: (i) a challenge against a panel of various HIV-
1s t r a i n s ,( ii) virus adsorption assays, (iii)c e l l - b a s e d
fusion assays, (iv) a gp120/CD4 capture ELISA, (v) time-
of-addition experiments, (vi) virucidal activity assays
with cell-free virus, and (vii) a challenge against cell-
associated virus. The data from these experiments sug-
gest that silver nanoparticles exerted anti-HIV activity at
an early stage of viral replication, most likely as a viruci-
dal agent or viral entry inhibitor.
Results
Cytotoxic effect
HeLa-CD4-LTR-b-gal cells (which express both CXCR4
and CCR5), MT-2 cells (lymphoid human cell line
expressing CXCR4), and human PBMC, were used as
models to assess silver nanoparticles’ cytotoxicity. By
means of a luciferase-based assay, the 50% cytotoxic
concentration (CC50) of silver nanoparticles was defined
as 3.9 ± 1.6 mg/mL against HeLa-CD4-LTR-b-gal cells,
as 1.11 ± 0.32 mg/mL against human PBMC, and 1.3 ±
0.58 mg/mL against MT-2 cells.
Range of antiviral activity
Silver nanoparticles of 30-50 nm were tested against a
panel of HIV-1 isolates using indicator cells in which
infection was quantified by a luciferase-based assay. Sil-
ver nanoparticles inhibited all strains, showing compar-
able antiviral potency against T-tropic, M-tropic, dual-
tropic, and resistant isolates (Table 1). The concentra-
tion of silver nanoparticles at which infectivity was
inhibited by 50% (IC50)r a n g e df r o m0 . 4 4t o0 . 9 1m g /
mL. The therapeutic index reflects a compound’s overall
activity by relating cytotoxicity (CC50) and effectiveness,
measured as the ability to inhibit infection (IC50), under
the same assay conditions. For these strains of HIV-1,
no significant reduction of the therapeutic index was
observed in strains that were resistant toward NNRTI,
NRTI, PI, and PII compared with laboratory strains cat-
alogued as wild type virus (Table 1).
Antiviral activity of silver nanoparticles and ions
To define that the observed antiviral effect of silver
nanoparticles is due to nanoparticles, rather than just
silver ions present in the solution, we also assessed the
antiviral activity of silver sulfadiazine (AgSD) and silver
nitrate (AgNO3), known antimicrobial silver salts that
exert their antimicrobial effect through silver ions [25].
Both salts inhibited HIV-1 infection in vitro (Table 2),
however, their therapeutic index is 12 times lower than
Table 1 Antiviral effect of silver nanoparticles against
HIV-1 strains
HIV-1 strain Tropism (co-
receptor)
IC50 (mg/
mL)*
HeLa cells
CC50 (mg/
mL)*
TI
IIIB T (X4) 0.44 (± 0.3) 3.9 (± 1.6) 8.9
Eli T (X4) 0.42 (± 0.2) 9.3
Beni T (X4) 0.19 (± 0.1) 20.5
96USSN20 T (X4)/M (R5) 0.36 (± 0.2) 12.5
Bal M (R5) 0.27 (± 0.2) 14.4
BCF01 M (R5) 0.37 (± 0.3) 10.5
AZTRV T (X4) 0.19 (± 0.01) 20.5
NNRTIRV T (X4) 0.61 (± 0.24) 6.4
PIRV T (X4) 0.91 (± 0.09) 4.3
3TCRV T (X4) 0.73 (± 0.12) 5.3
SaquinavirRV T (X4) 0.81 (± 0.11) 4.8
*Values represent the mean of the triplicate ± standard error of the mean.
NNRTI: non-nucleoside retrotranscriptase inhibitor, PI: protease inhibitor, RV:
resistant virus
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ver ions by itself have a lower efficiency than silver
nanoparticles.
Inhibition of viral adsorption
To confirm that the anti-HIV activity of silver nanopar-
ticles can be attributed to the inhibition of virus binding
or fusion to the cells, a virus adsorption assay was per-
formed [26]. One fusion inhibitor (Enfuvirtide) was
included as control specimen. Silver nanoparticles inhib-
ited the binding of IIIB virus to cells with an IC50 of
0.44 mg/mL. As expected, the fusion inhibitor inhibited
virus adsorption. These results indicate that silver nano-
particles inhibit the initial stages of the HIV-1 infection
cycle.
Inhibition of Env/CD4-mediated membrane fusion
A cell-based fusion assay was used to mimic the gp120-
CD4-mediated fusion process of HIV-1 to the host cell.
HL2/3 cells, which express HIV-1 Env on their surfaces
and Tat protein in their cytoplasms (effector cells) [27]
and HeLa-CD4-LTR-b-gal (indicator cells) can fuse as
the result of the gp120-CD4 interaction, and the amount
of fused cells can be measured with the b-gal reporter
gene. In the presence of a HL2/3-HeLa CD4 mixture,
silver nanoparticles efficiently blocked fusion between
both cells (Figure 1A) in a dose-dependent manner (1.0-
2.5 mg/mL range). This concentration range is close to
what we previously reported for silver nanoparticles
IC50. Known antiretroviral drugs used as controls, such
as UC781 (NNRTI), AZT (NRTI), and Indinavir (PI),
did not inhibit cell fusion in this cell-based fusion assay.
Silver nanoparticles interfere with gp120-CD4 interaction
The inhibitory activity of silver nanoparticles against the
gp120-CD4 interaction was also investigated in a com-
petitive gp120-capture ELISA. A constant amount of
gp120 was incubated for 10 min with increasing
amounts of silver nanoparticles, the mixture was then
added to a CD4-coated plate, and the amount of gp120
bound to the plate was quantified. Compared with the
control (0.0 mg/mL), there was a decrease of over 60%
of gp120 bound to CD4 coated-plates at the highest
dose of silver nanoparticles. As shown in Figure 1B, sig-
nificant decreases in absorbance values were observed in
the presence of silver nanoparticles (0.3-5.0 mg/mL).
The gp120-capture ELISA data, combined with the
results of the cell-based fusion assay, support the
hypothesis that silver nanoparticles inhibit HIV-1 infec-
tion by blocking the viral entry, particularly the gp120-
CD4 interaction.
Although silver nanoparticles feature characteristic
absorption at 400-500 nm [28] no interference to the
absorption signals of the ELISA assay was observed.
This can be assumed since the wells with the highest
concentration of silver nanoparticles did display higher
absorption levels (see Figure 1B) than the controls (0.0
mg/mL). Besides, the absorption levels obtained in the
presence of silver nanoparticles were lower than the
ones of the calibration curve (as defined by the
manufacturer).
Time (Site) of Intervention
To further determine the antiviral target of silver nano-
particles, a time-of-addition experiment was performed
using a single cycle infection assay. The time-of-addition
experiment was used to delimit the stage(s) of the viral
life cycle that is blocked by silver nanoparticles. HeLa
cells (expressing CD4, CXCR4 and CCR5) were infected
with HIV-1IIIB cell-free virus and either silver nanoparti-
cles (1.0 mg/mL), Tak-779 (2.0 μM), AZT (20.0 μM),
Indinavir (0.25 μM), or 118-D-24 (100.0 μM) was added
upon HIV-1 inoculation (time zero) or at various time
points post-inoculation. These antiretroviral drugs were
chosen as controls as they point out different stages of
the viral cycle (fusion or entry, retrotranscription, pro-
tease activity, and integration to the genome). As seen
in Figure 2(A-D), the antiviral activity of Tak-779, AZT,
Indinavir, and 118-D-24 started to decline after the
cycle stage that they target has passed. The fusion inhi-
bitor’s activity declined after 2 h (Figure 2A), RT inhibi-
tors after 4 h (Figure 2B), protease inhibitors after 7 h
(Figure 2C), and integrase inhibitors after 12 h (Figure
2D). In contrast, silver nanoparticles retained their anti-
viral activity even when added 12 h after the HIV inocu-
lation. These results show that silver nanoparticles
intervene with the viral life cycle at stages besides fusion
or entry. These post-entry stages cover a time period
between and including viral entry and the integration
into the host genome.
Virucidal activity of silver nanoparticles: inactivation of
cell-free and cell-associated virus
To study the effect that silver nanoparticles have over
the virus itself, cell-free and cell-associated HIV-1 were
treated with different concentrations of nanoparticles.
Cell-free and cell-associated virus are the infectious
HIV-1 forms present in semen and cervicovaginal secre-
tions and can be transmitted across the mucosal barrier
[29] Cell-associated virus includes infected cells that
transmit the infection by fusing with non-infected recep-
tor cells. By means of a luciferase-based assay, the
Table 2 Antiviral effect of silver salts and nanoparticles
against HIV-1
Silver
compound
IC50* HeLa cells CC50*T I
Silver
nanoparticles
0.44 mg/mL (± 0.3) 3.9 mg/mL (± 1.6) 8.9
Silver sulfadiazine 39.33 μg/mL (± 14.60) 28.25 μg/mL (± 7.28) 0.7
Silver nitrate 0.00059% (± 0.00022%) 0.00044% (± 0.00002%) 0.7
*Values represent the mean of the triplicate ± standard error of the mean.
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one M-tropic) was quantified after silver nanoparticle
treatment. As shown in Figure 3(A-B), silver nanoparti-
cle pretreatment of HIV-1IIIB and HIV-1Bal decreased
the infectivity of the viral particles after just 5 min of
exposure. The effect increased after 60 min of exposure
(particularly in Bal), indicating that silver nanoparticles
act directly on the virion, inactivating it.
Silver nanoparticles were also effective against the trans-
mission of HIV-1 infection mediated by chronically
infected PBMC and H9 (human lymphoid cell line). Trans-
mission was 50% reduced, even when both cell types were
treated with the nanoparticles for 1 min (Figure 4A-B).
Discussion
Silver nanoparticles proved to be an antiviral agent
against HIV-1, but its mode of action was not fully elu-
cidated. Is gp120 its principal target? Do silver nanopar-
t i c l e sa c ta se n t r yi n h i b i t o r s ?I nt h i ss t u d y ,w e
investigated the mode of antiviral action of silver nano-
particles against HIV-1. Our results reveal, for the first
time, that silver nanoparticles exert anti-HIV activity at
an early stage of viral replication, most likely as a viruci-
dal agent or viral entry inhibitor.
No significant difference was found in the antiviral
activities of silver nanoparticles against the different
drug-resistant strains (Table 1), so the mutations in
Figure 1 Inhibition of the gp120-CD4 interaction. (A) A cell-based fusion assay was used to mimic the gp120-CD4 mediated fusion of the
viral and host cell membranes. HL2/3 and HeLa-CD4-LTR-b-gal cells were incubated with a two-fold serial dilution of silver nanoparticles and
known antiretrovirals. The assay was performed in triplicate; the data points represent the mean ± s.e.m. (B) The degree of inhibition of the
gp120-CD4 protein binding was assessed with a gp120/CD4 ELISA capture in the presence or absence of silver nanoparticles. Gp120 protein was
pretreated for 10 min with a two-fold serial dilution of silver nanoparticles, then added to a CD4-coated plate. The assay was done twice; the
error bars indicate the s.e.m.
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affect the efficacy of silver nanoparticles. These results
further agree with previous findings, where it was pro-
ven that silver nanoparticles are broad-spectrum bio-
cides [30,31] HIV-1 strains found in the human
population can differ widely in their pathogenicity, viru-
lence, and sensitivity to particular antiretroviral drugs
[32] The fact that silver nanoparticles inhibit such a var-
ied panel of strains makes them an effective broad-spec-
trum agent against HIV-1. This particular property can
reduce the likelihood of the emergence of resistance and
the subsequent spread of infection.
Silver nanoparticles inhibited a variety of HIV-1
strains regardless of their tropism (Table 1). Variation in
gp120 among HIV strains is the major determinant of
differing tropism among strains, with the V3 loop of
gp120 recognizing the chemokine receptors CXCR4 (T-
tropic virus), CCR5 (M-tropic virus), or both (dual-tro-
pic virus) [33] The fact that silver nanoparticles inhib-
ited all tested strains indicates that their mode of action
does not depend on this determinant of cell tropism.
Elechiguerra et al. postulated that silver nanoparticles
undergo specific interaction with HIV-1 via preferential
binding with gp120 [7] If so, then our findings show
that inhibition by silver nanoparticles is not dependent
on the V3 loop, which has a net positive charge that
contributes to its role in determining viral co-receptor
tropism [34] Since silver particles have a positive surface
charge, the V3 loop would not be their preferred site of
interaction. Hence, the nanoparticles may possibly act as
attachment inhibitors by impeding the gp120-CD4 inter-
action, rather than as co-receptor antagonists that inter-
fere with the gp120-CXCR4/CCR5 contact [4]
By means of a viral adsorption assay, it was shown
that silver nanoparticles’ mechanism of anti-HIV action
is based on the inhibition of the initial stages of the
HIV-1 cycle. In addition, the gp120-capture ELISA data
(Figure 1B), combined with the results of the cell-based
fusion assay (Figure 1A), supported the hypothesis that
silver nanoparticles inhibit HIV-1 infection by blocking
viral entry, particularly the gp120-CD4 interaction. The
observations previously made by STEM analysis support
this idea, since silver nanoparticles were seen to bind
protein structures distributed over the viral membrane
[7] If silver nanoparticles do not bind to the V3 loop,
then they might preferentially interact with the negative
cavity of gp120 that binds to CD4 [35] The attraction
between CD4 and gp120 is mostly electrostatic, with the
primary end of CD4 binding in a recessed pocket on
gp120, making extensive contacts over ~800 Å
2 of the
gp120 surface [36]
In addition, silver nanoparticles might interact with
the two disulfide bonds located in the carboxyl half of
the HIV-1 gp120 glycoprotein, an area that has been
Figure 2 Time-of-addition experiment. HeLa-CD4-LTR-b-gal cells
were infected with HIV- 1IIIB, and silver nanoparticles (1 mg/mL) and
different antiretrovirals were added at different times post infection.
Activity of silver nanoparticles was compared with (A) Fusion
inhibitors (Tak-779, 2 μM), (B) RT inhibitors (AZT, 20 μM), (C) Protease
inhibitors (Indinavir, 0.25 μM), and (D) Integrase inhibitors (118-D-24,
100 μM). Dashed lines indicate the moment when the activity of
the silver nanoparticles and the antiretroviral differ. The assay was
performed in triplicate; the data points represent the mean and the
colored lines are nonlinear regression curves done with SigmaPlot
10.0 software.
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ions bind to sulfhydryl groups, which lead to protein
denaturation by the reduction of disulfide bonds [38]
Therefore, we hypothesize that silver nanoparticles not
only bind to gp120 but also modify this viral protein by
denaturing its disulfide-bonded domain located in the
CD4 binding region. This can be seen in our results of
silver nanoparticles’ capacity to more strongly diminish
residual infectivity of viral particles after 60 minutes of
incubation than after 5 minutes of incubation (Figure 3).
Since the antiviral effect of silver nanoparticles increases
with the incubation time, we can hypothesize that silver
nanoparticles initially bind to gp120 knobs and then
inhibit infection by irreversibly modifying these viral
structures. However, further research is needed to define
if silver nanoparticles interact with the negatively
charged cavity and the two disulfide bonds located in
gp120’s CD4 binding region.
Figure 3 Virucidal activity of silver nanoparticles against M and T tropic HIV-1. Serial two-fold dilutions of silver nanoparticles were added
to 10
5 TCID50 of HIV-1Bal (A) and HIV-1IIIB (B) cell-free virus with a 0.2-0.5 m.o.i. After incubation for 5 min and 60 min, the mixtures were
centrifuged three times at 10,000 rpm, the supernatant fluids removed, and the pellets washed three times. The final pellets were placed into
96-well plates with HeLa-CD4-LTR-b-gal cells. Assessment of HIV-1 infection was made with a luciferase-based assay. The percentage of residual
infectivity after silver nanoparticle treatment was calculated with respect to the positive control of untreated virus. The assay was performed in
triplicate; the data points represent the mean, and the solid lines are nonlinear regression curves done with SigmaPlot 10.0 software.
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pounds that target the envelope because of the high rate
of substitutions in the variable regions of the Env pro-
tein. However, since the positions of the cysteine resi-
dues, the disulfide bonding pattern in gp120, and the
ability of gpl20 to bind to the viral receptor CD4 are
highly conserved between isolates [39] the development
of resistance to silver nanoparticles would be
complicated.
By comparing the antiviral effect (measured by the
therapeutic index) of silver nanoparticles with two com-
monly used silver salts (AgSD and AgNO3), it was
observed that silver ions by themselves are less efficient
than silver nanoparticles. Hence, if the observed anti-
HIV-1 activity of silver nanoparticles would just have
been due to silver ions present in the nanoparticles’
solution, the therapeutic index would have been lower.
High activity of silver nanoparticles is suggested to be
due to species difference as they dissolve to release Ag
0
(atomic) and Ag
+ (ionic) clusters, whereas silver salts
release Ag
+ only [40]
The time-of-addition experiments further confirmed
silver nanoparticles as entry inhibitors (Figure 2). In
addition, it was revealed that silver nanoparticles have
other sites of intervention on the viral life cycle, besides
fusion or entry. Since silver ions can complex with elec-
tron donor groups containing sulfur, oxygen, or nitrogen
that are normally present as thiols or phosphates on
Figure 4 Treatment of HIV-1 cell-associated virus. Chronically HIV-1-infected H9 (A) and PBMC (B) cells were incubated with serial two-fold
dilutions of silver nanoparticles for 1 min and 60 min. Treated cells were centrifuged, washed three times with cell culture media, and then
added to TZM-bl cells. Assessment of HIV-1 infection was made with a luciferase-based assay after 48 h. The assay was performed in triplicate;
the error bars indicate the s.e.m.
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post-entry stages of infection by blocking HIV-1 pro-
teins other than gp120, or reducing reverse transcription
or proviral transcription rates by directly binding to the
RNA or DNA molecules. Besides, earlier studies have
shown that silver nanoparticles suppress the expression
of TNF-a [42] which is a cytokine that plays a pivotal
role in HIV-1 pathogenesis by incrementing HIV-1 tran-
scription [43] The inhibition of the TNF-a activated
transcription might also beat a r g e tf o rt h ea n t i - H I V
activity of silver nanoparticles. Having such a varied
panel of targets in the HIV-1 replication cycle makes sil-
ver nanoparticles an agent that is not prone to contri-
bute to the appearance of resistant strains.
Silver nanoparticles proved to be virucidal to cell-free
and cell-associated HIV-1 as judged by viral infectivity
assays (Figures 3 and 4). HIV infectivity is effectively
eliminated following short exposure of isolated virus to
silver nanoparticles. Silver nanoparticle treatment of
chronically infected H9
+ cells as well as human PBMC
+
resulted in decreased infectivity.
A virucide must operate quickly and effectively in pre-
venting infection of vulnerable target cells. According to
Borkow et al. (1997), an ideal retrovirucidal agent should
act directly on the virus, act at replication steps prior to
integration of proviral DNA into the infected host cell
genome, be absorbable by uninfected cells in order to
provide a barrier to infection by residual active virus, and
be effective at non-cytotoxic concentrations readily
attainable in vivo [44] Silver nanoparticles act directly on
the virus at steps that prevent integration inside the host
cell, but further pharmacokinetic, pharmacodynamic, and
toxicological studies in animal models are needed to
define safety parameters for the use of silver nanoparti-
cles as preventive tools for HIV-1 transmission.
Conclusions
Finally, we propose that the antiviral activity of silver
nanoparticles results from their inhibition of the interac-
tion between gp120 and the target cell membrane recep-
tors. According to our results, this mode of antiviral
action allows silver nanoparticles to inhibit HIV-1 infec-
tion regardless of viral tropism or resistance profile, to
bind to gp120 in a manner that prevents CD4-depen-
dent virion binding, fusion, and infectivity, and to block
HIV-1 cell-free and cell-associated infection, acting as a
virucidal agent. In conclusion, silver nanoparticles are
effective virucides as they inactivate HIV particles in a
short period of time, exerting their activity at an early
stage of viral replication (entry or fusion) and at post-
e n t r ys t a g e s .T h ed a t ap r e s e n t e dh e r ec o n t r i b u t et oa
new and still largely unexplored area; the use of nano-
materials against specific targets of viral particles.
Methods
Silver compounds
Commercially manufactured 30-50 nm silver nanoparti-
cles, surface coated with 0.2 wt% PVP, were used
(Nanoamor, Houston, TX). Stock solutions of silver
nanoparticles, silver sulfadiazine (Sigma-Aldrich) and sil-
ver nitrate (Sigma-Aldrich) were prepared in RPMI 1640
cell culture media. Following serial dilutions of the stock
were made in culture media.
Cells, HIV-1 isolates, and antiretrovirals
HeLa-CD4-LTR-b-gal cells, MT-2 cells, HL2/3 cells, H9
cells, TZM-bl cells, HIV-1IIIB,H I V - 1 Bal,H I V - 1 BCF01,
HIV-196USSN20, AZT, Indinavir, 118-D-24, Tak-779, and
Enfuvirtide were obtained through the AIDS Research
and Reference Reagent Program, NIH. HIV-1Eli and
HIV-1Beni are clinical isolates from patients from the
Ruth Ben-Ari Institute of Clinical Immunology and
AIDS Center, Israel. They were kindly donated by Gadi
Borkow. Aliquots of cell-free culture viral supernatants
were used as viral inocula. Peripheral blood mononuc-
lear cells (PBMC) were isolated from healthy donors
using Histopaque-1077 (Sigma-Aldrich) according to the
manufacturer’si n s t r u c t i o n s .U C 7 8 1w a sk i n d l yd o n a t e d
by Dr. Gadi Borkow.
Cytotoxicity assays
A stock solution of silver nanoparticles was two-fold
diluted to desired concentrations in growth medium and
subsequently added into 96-wells plates containing
HeLa-CD4-LTR-b-gal cells, PBMC and MT-2 cells (5 ×
10
4 cells/well). Microtiter plates were incubated at 37°C
in a 5% CO2 air humidified atmosphere for a further 2
days. Assessments of cell viability were carried out using
a CellTiter-Glo® Luminescent Cell Viability Assay (Pro-
mega). The 50% cytotoxic concentration (CC50)w a s
defined based on the percentage cell survival relative to
the positive control.
HIV-1 infectivity inhibition assays
Serial two-fold dilutions of silver nanoparticles were
mixed with 10
5 TCID50 of HIV-1 cell-free virus and
added to HeLa-CD4-LTR-b-gal cells with a 0.2-0.5 multi-
plicity of infection [7] HIV-1 infection was assessed after
two days of incubation by quantifying the activity of the
b-galactosidase produced after infection with the Beta-
Glo Assay System (Promega). The 50% inhibitory con-
centration (IC50) was defined according to the percentage
of infectivity inhibition relative to the positive control.
Virus adsorption assays
In this assay the inhibitory effects of silver nanoparticles
on virus adsorption to HeLa-CD4-LTR-b-gal cells were
measured as previously described [26] HeLa-CD4-LTR-
b-gal cells (5 × 10
4 cells/well) were incubated with
HIVIIIB in the absence or presence of serial dilutions of
silver nanoparticles and Enfuvirtide. After 2 h of
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with 1× PBS to remove the unadsorbed virus particles.
Then the cells were incubated for 48 h, and the amount
of viral infection was quantified with the Beta-Glo Assay
System (Promega).
Cell-based fusion assay
HeLa-derived HL2/3 cells, which express the HIV-1HXB2
Env, Tat, Gag, Rev, and Nef proteins, were co-cultured
with HeLa-CD4-LTR-b-gal cells at a 1:1 cell density
ratio (2.5 × 10
4 cells/well each) for 48 h in the absence
or presence of two-fold dilutions of silver nanoparticles,
U C 7 8 1 ,A Z T ,a n dI n d i n a v i ri no r d e rt oe x a m i n e
whether the compounds interfered with the binding pro-
cess of HIV-1 Env and the CD4 receptor. Upon fusion
of both cell lines, the Tat protein from HL2/3 cells acti-
vates b-galactosidase indicator gene expression in HeLa-
CD4-LTR-b-gal cells [45,27] b-gal activity was quanti-
fied with the Beta-Glo Assay System (Promega). The
percentage of inhibition of HL2/3-HeLa CD4 cell fusion
was calculated with respect to the positive control of
untreated cells.
HIV-1 gp120/CD4 ELISA
A gp120 capture ELISA (ImmunoDiagnostics, Inc.,
Woburn, MA) was used to test the inhibitory activity of
silver nanoparticles against gp120-CD4 binding. Briefly,
recombinant HIV-1IIIB gp120 protein (100 ng/mL) was
pre-incubated for 10 min in the absence or presence of
serial two-fold dilutions of silver nanoparticles, and then
added to a CD4-coated plate. The amount of captured
gp120 was detected by peroxidase-conjugated murine
anti-gp120 MAb. In separate experiments, gp120 (100
ng/mL) was added to CD4-coated plates pretreated with
silver nanoparticles for a 10 min period. Before the addi-
tion of the gp120 protein, plates were washed three
times to remove unbound silver nanoparticles [27]
Time-of-addition experiments
HeLa-CD4-LTR-b-gal cells were infected with 10
5
TCID50 of HIV-1 cell-free virus with a 0.2-0.5 multipli-
city of infection (m.o.i.). Silver nanoparticles (1 mg/mL),
Tak-779 (fusion inhibitor, 2 μM), AZT (NRTI, 20 μM),
Indinavir (protease inhibitor, 0.25 μM), and 118-D-24
(integrase inhibitor, 100 μM) were then added at differ-
ent times (0, 1, 2, 3 ... 12 h) after infection [3,31] Infec-
tion inhibition was quantified after 48 h by measuring
b-gal activity with the Beta-Glo Assay System.
Virucidal activity assay
Serial two-fold dilutions of silver nanoparticles were
added to 10
5 TCID50 of HIV-1IIIB and HIV-1Bal cell-free
virus with a 0.2-0.5 m.o.i. After incubation for 5 min
and 60 min at room temperature, the mixtures were
centrifuged three times at 10,000 rpm, the supernatant
fluids removed, and the pellets washed three times. The
final pellets were resuspended in DMEM and placed
into 96-well plates with HeLa-CD4-LTR-b-gal cells. The
cells were incubated in a 5% CO2 humidified incubator
at 37°C for 2 days. Assessment of HIV-1 infection was
made with the Beta-Glo Assay System. The percentage
of residual infectivity after silver nanoparticle treatment
was calculated with respect to the positive control of
untreated virus [31]
Treatment of HIV-1 cell-associated virus
Chronically HIV-1-infected PBMC and H9 cells were
incubated with serial two-fold dilutions of silver nano-
particles for 1 min and 60 min. Treated cells were cen-
trifuged, washed three times with cell culture media,
and then added to TZM-bl cells. HIV-1 infection trig-
gers, through the Tat protein, b-galactosidase expression
in TZM-bl cells. b-gal activity was quantified with the
Beta-Glo Assay System.
Statistical analysis
Graphs show values of the means ±standard deviations
from three separate experiments, each of which was car-
ried out in duplicate. Time-of-addition experiment
graphs are nonlinear regression curves done with Sigma-
Plot 10.0 software.
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